A hybrid approach based on ELECTRE III-genetic algorithm and TOPSIS method for selection of optimal COVID-19 vaccines

IF 1.9 Q3 MANAGEMENT Journal of Multi-Criteria Decision Analysis Pub Date : 2021-11-15 DOI:10.1002/mcda.1772
Roberto Louis Forestal, Shih-Ming Pi
{"title":"A hybrid approach based on ELECTRE III-genetic algorithm and TOPSIS method for selection of optimal COVID-19 vaccines","authors":"Roberto Louis Forestal,&nbsp;Shih-Ming Pi","doi":"10.1002/mcda.1772","DOIUrl":null,"url":null,"abstract":"<p>COVID-19 pandemic poses unprecedented challenges to the world health system, prompting academics and health professionals to develop appropriate solutions. Researchers reported different COVID-19 vaccines introduced by institutions and companies around the globe, which are at different stages of development. However, research developing an integrated framework for selecting and ranking the optimal potential vaccine against COVID-19 is minimal. This paper aimed to fill this gap by using a hybrid methodology based on ELimination Et Choice Translating REality III (ELECTRE III)–Genetic Algorithm (GA) and Technique of Order Preference Similarity to the Ideal Solution (TOPSIS) approach to select the optimal SARS-CoV-2 vaccine. ELECTRE III method yields a fathomable analysis of the concordance index, while GA is known for its ability to disaggregate decision-making preferences from holistic decisions. TOPSIS is preferred for picking an ideal and an anti-ideal solution. Thus, combining ELECTRE III-GA and TOPSIS is considered the best model to assess vaccines against the pandemic. The results confirm that the best vaccines rely on a high level of safety, efficacy, and availability. Our developed evaluation framework can help healthcare professionals and researchers gain research information and make critical decisions regarding potential vaccines against the disease.</p>","PeriodicalId":45876,"journal":{"name":"Journal of Multi-Criteria Decision Analysis","volume":"29 1-2","pages":"80-91"},"PeriodicalIF":1.9000,"publicationDate":"2021-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/mcda.1772","citationCount":"17","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Multi-Criteria Decision Analysis","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/mcda.1772","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MANAGEMENT","Score":null,"Total":0}
引用次数: 17

Abstract

COVID-19 pandemic poses unprecedented challenges to the world health system, prompting academics and health professionals to develop appropriate solutions. Researchers reported different COVID-19 vaccines introduced by institutions and companies around the globe, which are at different stages of development. However, research developing an integrated framework for selecting and ranking the optimal potential vaccine against COVID-19 is minimal. This paper aimed to fill this gap by using a hybrid methodology based on ELimination Et Choice Translating REality III (ELECTRE III)–Genetic Algorithm (GA) and Technique of Order Preference Similarity to the Ideal Solution (TOPSIS) approach to select the optimal SARS-CoV-2 vaccine. ELECTRE III method yields a fathomable analysis of the concordance index, while GA is known for its ability to disaggregate decision-making preferences from holistic decisions. TOPSIS is preferred for picking an ideal and an anti-ideal solution. Thus, combining ELECTRE III-GA and TOPSIS is considered the best model to assess vaccines against the pandemic. The results confirm that the best vaccines rely on a high level of safety, efficacy, and availability. Our developed evaluation framework can help healthcare professionals and researchers gain research information and make critical decisions regarding potential vaccines against the disease.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
基于ELECTRE iii -遗传算法和TOPSIS方法的COVID-19最佳疫苗选择混合方法
COVID-19大流行给世界卫生系统带来了前所未有的挑战,促使学术界和卫生专业人员制定适当的解决方案。研究人员报告说,全球各机构和企业推出的新冠病毒疫苗处于不同的开发阶段。然而,针对COVID-19的最佳潜在疫苗选择和排名制定综合框架的研究很少。本文旨在通过基于消除选择翻译现实III (ELECTRE III) -遗传算法(GA)和顺序偏好相似于理想解(TOPSIS)方法的混合方法来选择最优SARS-CoV-2疫苗,填补这一空白。ELECTRE III方法对一致性指数进行了深不可测的分析,而GA则以其从整体决策中分解决策偏好的能力而闻名。TOPSIS是选择理想和反理想解决方案的首选方法。因此,将ELECTRE III-GA和TOPSIS结合起来被认为是评估大流行疫苗的最佳模型。结果证实,最好的疫苗依赖于高水平的安全性、有效性和可得性。我们开发的评估框架可以帮助医疗保健专业人员和研究人员获得研究信息,并就针对该疾病的潜在疫苗做出关键决定。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
4.70
自引率
10.00%
发文量
14
期刊介绍: The Journal of Multi-Criteria Decision Analysis was launched in 1992, and from the outset has aimed to be the repository of choice for papers covering all aspects of MCDA/MCDM. The journal provides an international forum for the presentation and discussion of all aspects of research, application and evaluation of multi-criteria decision analysis, and publishes material from a variety of disciplines and all schools of thought. Papers addressing mathematical, theoretical, and behavioural aspects are welcome, as are case studies, applications and evaluation of techniques and methodologies.
期刊最新文献
A Multi-Objective Optimization for Determination of Sustainable Crop Pattern Using Game Theory A Multi-Criteria Decision Support Tool for Shared Decision Making in Clinical Consultation Issue Information A Bibliometric Exploration of Multiple Criteria Decision Aid and Clustering—A Conceptual Taxonomy Monitoring Sustainable Development Goals: Stepwise Benchmarking Approach
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1